Enter multiple symbols separated by commas

Cramer: Why Covidien is Now a Buy

Now that Covidien is spinning off its pharmaceuticals business, the stock is a buy, “Mad Money” host Jim Cramer said Monday.

The company , which makes medical devices and supplies, announced last week that it intends to make its pharmaceutical business a standalone public company.

“This is all about streamlining Covidien so the company can focus on what it does best—devices,” Cramer said, pointing out that the new CEO comes from a medical device background within the company.

He also thinks the pharma division has been dragging the rest of the company down. It’s historically been a lot more volatile and has much lower margins than Covidien’s fast-growing medical device franchise.

“Covidien has been trying to remake itself for a long time,” Cramer said, “and spinning off the pharma business is just the latest step as the company transforms from a cash-cow like conglomerate into a faster-growing, more nimble, and more profitable medical technology business.”

Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

Contact Mad Money

  • Showtimes

    Monday - Friday 6p ET
    Saturday 8a, 1p, 7p SYD
    Sunday 12a, 1a, 8a, 7p SYD
    New Zealand
    Saturday 10a, 3p, 9p NZ
    Sunday 2a, 3a, 10a, 9p NZ
  • Jim Cramer

    Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

Mad Money Moments

Cramer's New Book